申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US10364256B2
公开(公告)日:2019-07-30
The present invention relates to biaryl pyrazole compounds of Formula (I)
methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US20180282349A1
公开(公告)日:2018-10-04
The present invention relates to biaryl pyrazole compounds of Formula (I)
methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
[EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2017060854A1
公开(公告)日:2017-04-13
The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
本发明涉及双芳基吡唑化合物、它们的制备方法、含有它们的药物组合物及其作为NRF2调节剂的应用。
Synthesis and in vitro antimycobacterial activity of compounds derived from (R)- and (S)-2-amino-1-butanol – The crucial role of the configuration
作者:Georgi M. Dobrikov、Violeta Valcheva、Margarita Stoilova-Disheva、Georgi Momekov、Pavleta Tzvetkova、Angel Chimov、Vladimir Dimitrov
DOI:10.1016/j.ejmech.2011.11.035
日期:2012.2
The synthesis of 47 structurally diverse compounds incorporating the (R)-2-amino-1-butanol motif has been realized. Ten of these compounds were found to exhibit in vitro specific activity against Mycobacterium tuberculosis H37Rv in a MIC range of 0.65 mu M-14.03 mu M. Five of the most active compounds 11, 22, 23, 31 and 42(5.7-11.1 fold more active than ethambutol) can be outlined with very low cytotoxicity towards human embryonal kidney non-tumour cells (SI ranging from 91.2 to 375.4). For the purpose of comparison the (S)-enantiomers of these most active compounds have been synthesized and evaluated towards M. tuberculosis H(37)Rv showing no activity even at 20-32 fold higher concentrations. (C) 2011 Elsevier Masson SAS. All rights reserved.